Tempus AI Inc sees stock rise amid market decline
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 02 Jan 26
Source: Coinmarketcap
Tempus AI Inc's stock rose by 5.06% as it crossed above the 5-day SMA, showcasing a strong performance despite the broader market's downturn.
This increase comes amid a decline in the Nasdaq-100 by 0.53% and the S&P 500 by 0.18%, indicating a potential sector rotation as investors seek opportunities in specific stocks like Tempus AI. The stock's resilience suggests that it is attracting interest even when the overall market is weak.
The implications of this movement could indicate a shift in investor sentiment towards Tempus AI, possibly driven by its unique offerings or market positioning, which may provide a buffer against broader market trends.
Analyst Views on TEM
Wall Street analysts forecast TEM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TEM is 86.00 USD with a low forecast of 76.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
5 Buy
6 Hold
0 Sell
Moderate Buy
Current: 64.570
Low
76.00
Averages
86.00
High
105.00
Current: 64.570
Low
76.00
Averages
86.00
High
105.00
About TEM
Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. It offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. It provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
